Acromegaly

The PBS subsidises pasireotide and pegvisomant for patients with acromegaly.

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with pasireotide and pegvisomant under the National Health Act 1953, section 100 for patients with acromegaly.

Patients must be eligible for the PBS and meet the relevant criteria in the restrictions.

The Schedule of Pharmaceutical Benefits on the PBS website lists restrictions for prescribing pasireotide and pegvisomant.

Section 100 arrangements

pasireotide and pegvisomant

These items are only PBS-subsidised for non-admitted patients, day admitted patients, or patients on discharge who are attending:

  • an approved private hospital
  • a public hospital.

These items aren’t PBS-subsidised for public hospital in-patients. You must include the hospital name and provider number on the authority application form.

Authority applications

Applying for initial treatment

Please note: You don’t need to complete this application in writing when you request PBS authority online.

Applications for initial authority approval to prescribe PBS-subsidised pasireotide or pegvisomant to treat acromegaly can be made:

All written applications for pasireotide must include:

All written applications for pegvisomant must include:

Applying for continuing treatment

Applications for continuing authority approval to prescribe PBS-subsidised pasireotide or pegvisomant to treat acromegaly can be made either:

More information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 1 October 2024.
QC 35096